Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study

Arcturus Therapeutics Holdings Inc. announced positive interim results from its Phase 2 study of ARCT-810 for ornithine transcarbamylase deficiency, indicating that the treatment is generally safe and well tolerated while showing encouraging activity across key urea cycle biomarkers. The company also introduced LUNAR 2.0™, its next-generation mRNA delivery platform, which will be integrated into the ongoing Phase 2 study later this year. This development is seen as a validation of Arcturus' mRNA liver therapeutics platform.